MX9702170A - Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres. - Google Patents
Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.Info
- Publication number
- MX9702170A MX9702170A MX9702170A MX9702170A MX9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- aromatase inhibitors
- men
- treating
- preparation
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 3
- 229940046844 aromatase inhibitors Drugs 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 206010002261 Androgen deficiency Diseases 0.000 title abstract 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 abstract 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
- 229940078010 arimidex Drugs 0.000 abstract 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 abstract 1
- 229950004810 atamestane Drugs 0.000 abstract 1
- 229960004421 formestane Drugs 0.000 abstract 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se relaciona con el uso de inhibidores de la aromatasa en la preparacion de un fármaco para tratar una deficiencia de androgeno relativa en los hombres. Los inhibidores de la aromatasa selectivos, tales como por ejemplo atamestano. formestano, pentrozol, arimidex, fadrozol, CGS 20267 y/o vorozol, se utilizan de preferencia para preparar el fármaco de acuerdo con la invencion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4435368A DE4435368A1 (de) | 1994-09-22 | 1994-09-22 | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
PCT/EP1995/003733 WO1996009057A1 (de) | 1994-09-22 | 1995-09-22 | Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9702170A true MX9702170A (es) | 1998-04-30 |
Family
ID=6529877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702170A MX9702170A (es) | 1994-09-22 | 1995-09-22 | Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres. |
Country Status (21)
Country | Link |
---|---|
US (1) | US5861389A (es) |
EP (1) | EP0782450B1 (es) |
JP (1) | JPH10505848A (es) |
KR (1) | KR100387345B1 (es) |
CN (1) | CN1104243C (es) |
AT (1) | ATE241989T1 (es) |
AU (1) | AU707997B2 (es) |
BR (1) | BR9509155A (es) |
CA (1) | CA2200195C (es) |
CZ (1) | CZ76097A3 (es) |
DE (2) | DE4435368A1 (es) |
DK (1) | DK0782450T3 (es) |
ES (1) | ES2199255T3 (es) |
FI (1) | FI971207A (es) |
HU (1) | HUT76981A (es) |
MX (1) | MX9702170A (es) |
NO (1) | NO971349L (es) |
PL (1) | PL182909B1 (es) |
PT (1) | PT782450E (es) |
SK (1) | SK36397A3 (es) |
WO (1) | WO1996009057A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19610645A1 (de) * | 1996-03-06 | 1997-09-11 | Schering Ag | Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann |
US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
CA2409647C (en) | 2000-05-26 | 2012-07-03 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6607755B2 (en) | 2001-06-21 | 2003-08-19 | Michael Donald Farley | Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios |
US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US7173064B2 (en) * | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
ATE406153T1 (de) * | 2001-07-09 | 2008-09-15 | Repros Therapeutics Inc | Verfahren und materialien für die behandlung des testosteron-mangels bei männern |
AU2002364949C1 (en) * | 2001-12-06 | 2008-05-29 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US6586417B1 (en) | 2002-04-22 | 2003-07-01 | Nutrisport Pharmacal, Inc. | Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans |
AU2003203010A1 (en) * | 2003-01-13 | 2004-08-13 | Michael Donald Farley | Improvements in or relating to anti-aromatase composition |
WO2004064814A1 (en) * | 2003-01-13 | 2004-08-05 | Michael Donald Farley | Improvements in or relating to anti-aromatase composition |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
WO2006019916A1 (en) * | 2004-07-14 | 2006-02-23 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
EP1848416A4 (en) * | 2005-02-04 | 2008-09-24 | Repros Therapeutics Inc | METHOD AND MATERIALS USING TRANS-CLOMIPHES FOR TREATING MALE INACCURIBILITY |
PL383444A1 (pl) * | 2005-03-22 | 2008-03-17 | Repros Therapeutics Inc. | Sposoby dawkowania trans-klomifenu |
MX2008014825A (es) | 2006-05-22 | 2008-12-01 | Hormos Medical Ltd | Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana. |
ME00996B (me) | 2007-10-16 | 2012-10-20 | Repros Therapeutics Inc | Trans-klomifen za liječenje metaboličkog sindroma |
US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
US20090215738A1 (en) * | 2008-02-26 | 2009-08-27 | Michael Charles Scally | Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake |
WO2011016814A1 (en) * | 2009-08-07 | 2011-02-10 | Kneller Bruce W | 5α-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR |
US20090306031A1 (en) * | 2009-08-07 | 2009-12-10 | Kneller Bruce W | 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US20140235601A1 (en) * | 2011-08-09 | 2014-08-21 | Kenneth W. Adams | Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males |
PT2753312T (pt) * | 2011-09-08 | 2017-02-03 | Mereo Biopharma 2 Ltd | Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas |
CN102641502A (zh) * | 2012-04-25 | 2012-08-22 | 中国农业大学 | 芳香酶抑制剂的新用途 |
WO2014070523A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4322416A (en) * | 1980-06-27 | 1982-03-30 | Merrell Dow Pharmaceuticals Inc. | 10-Alkynyl steroids |
US4289762A (en) * | 1980-06-27 | 1981-09-15 | Merrell Dow Pharmaceuticals Inc. | 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors |
DE3362176D1 (en) * | 1982-07-14 | 1986-03-27 | Akzo Nv | Novel 19-thio-androstane derivatives |
DE3322285A1 (de) * | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3539244A1 (de) * | 1985-11-01 | 1987-05-07 | Schering Ag | 1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
GB8531745D0 (en) * | 1985-12-24 | 1986-02-05 | Erba Farmitalia | 10beta-alkynyl-4-9(11)-estradiene derivatives |
GB8615092D0 (en) * | 1986-06-20 | 1986-07-23 | Erba Farmitalia | Androst-4-ene-317-diones |
DE3705990A1 (de) * | 1987-02-20 | 1988-09-01 | Schering Ag | 1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3926365A1 (de) * | 1989-08-04 | 1991-02-07 | Schering Ag | Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln |
GB9226620D0 (en) * | 1992-12-21 | 1993-02-17 | Fujisawa Pharmaceutical Co | A new compound fr 901537,production thereof and use thereof |
-
1994
- 1994-09-22 DE DE4435368A patent/DE4435368A1/de not_active Withdrawn
-
1995
- 1995-09-22 US US08/809,582 patent/US5861389A/en not_active Expired - Fee Related
- 1995-09-22 CA CA002200195A patent/CA2200195C/en not_active Expired - Fee Related
- 1995-09-22 DE DE59510714T patent/DE59510714D1/de not_active Expired - Fee Related
- 1995-09-22 EP EP95934094A patent/EP0782450B1/de not_active Expired - Lifetime
- 1995-09-22 AT AT95934094T patent/ATE241989T1/de not_active IP Right Cessation
- 1995-09-22 PL PL95319299A patent/PL182909B1/pl not_active IP Right Cessation
- 1995-09-22 MX MX9702170A patent/MX9702170A/es not_active IP Right Cessation
- 1995-09-22 CN CN95195216A patent/CN1104243C/zh not_active Expired - Fee Related
- 1995-09-22 DK DK95934094T patent/DK0782450T3/da active
- 1995-09-22 CZ CZ97760A patent/CZ76097A3/cs unknown
- 1995-09-22 KR KR1019970701850A patent/KR100387345B1/ko not_active IP Right Cessation
- 1995-09-22 AU AU36518/95A patent/AU707997B2/en not_active Ceased
- 1995-09-22 ES ES95934094T patent/ES2199255T3/es not_active Expired - Lifetime
- 1995-09-22 PT PT95934094T patent/PT782450E/pt unknown
- 1995-09-22 BR BR9509155A patent/BR9509155A/pt not_active Application Discontinuation
- 1995-09-22 JP JP8510608A patent/JPH10505848A/ja active Pending
- 1995-09-22 SK SK363-97A patent/SK36397A3/sk unknown
- 1995-09-22 WO PCT/EP1995/003733 patent/WO1996009057A1/de not_active Application Discontinuation
- 1995-09-22 HU HU9701697A patent/HUT76981A/hu unknown
-
1997
- 1997-03-21 NO NO971349A patent/NO971349L/no unknown
- 1997-03-21 FI FI971207A patent/FI971207A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100387345B1 (ko) | 2003-08-30 |
DE59510714D1 (de) | 2003-07-10 |
PL319299A1 (en) | 1997-08-04 |
PL182909B1 (pl) | 2002-04-30 |
ES2199255T3 (es) | 2004-02-16 |
BR9509155A (pt) | 1997-10-14 |
EP0782450A1 (de) | 1997-07-09 |
AU707997B2 (en) | 1999-07-29 |
CZ76097A3 (en) | 1997-07-16 |
CA2200195A1 (en) | 1996-03-28 |
AU3651895A (en) | 1996-04-09 |
HUT76981A (hu) | 1998-01-28 |
DE4435368A1 (de) | 1996-03-28 |
US5861389A (en) | 1999-01-19 |
EP0782450B1 (de) | 2003-06-04 |
NO971349D0 (no) | 1997-03-21 |
FI971207A0 (fi) | 1997-03-21 |
CN1158570A (zh) | 1997-09-03 |
FI971207A (fi) | 1997-03-21 |
WO1996009057A1 (de) | 1996-03-28 |
KR970706002A (ko) | 1997-11-03 |
SK36397A3 (en) | 1997-08-06 |
ATE241989T1 (de) | 2003-06-15 |
JPH10505848A (ja) | 1998-06-09 |
PT782450E (pt) | 2003-09-30 |
NO971349L (no) | 1997-05-16 |
CN1104243C (zh) | 2003-04-02 |
DK0782450T3 (da) | 2003-08-18 |
CA2200195C (en) | 2008-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9702170A (es) | Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres. | |
BG103003A (en) | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical chelateforming means with a metal | |
TW366342B (en) | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss | |
DE69726577D1 (en) | Kristallin form i von clarithromycin | |
MY114014A (en) | Imidazole compounds, compositions and use | |
IL138476A0 (en) | Method for treating pharmaceutical compositions by special use of anti-oxidant | |
IL125223A0 (en) | Novel substituted imidazole compounds | |
HK1022624A1 (en) | Novel substituted imidazole compounds. | |
TR199903331T2 (xx) | Farnesil protein transferas engelleyicileri. | |
MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
IL141686A0 (en) | Methods of treating hypertension and compositions for use therein | |
MX9704037A (es) | 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos. | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
DE69120287D1 (en) | Aminosulfonylharnstoff-acat-inhibitoren | |
SE9802937D0 (sv) | Novel compounds | |
IL125821A0 (en) | A pharmaceutical composition containing dehydroepiandrosterone and aromatase inhibitors and use thereof | |
DK1189627T3 (da) | Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden | |
MX9704035A (es) | 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos. | |
MX9704036A (es) | 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso. | |
NZ335015A (en) | use of selective aromatase inhibitors for treating a relative androgen deficiency in men | |
UA23046C2 (uk) | Протимікробhий засіб | |
GB9809555D0 (en) | Use of neuropeptide Y receptor agonists for treating migraine | |
UA32146A (uk) | Спосіб оцінки ефективності лікування пародонтита | |
MX9710304A (es) | Composiciones para la preparacion de cuero. | |
UA32314A (uk) | Спосіб лікування некротичного панкреатиту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |